TORONTO, Feb. 8 /CNW/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical
company dedicated to the development and commercialization of cancer
therapies, today announced that Dr. Alan M. Ezrin, President and Chief
Executive Officer of the Company, will participate as a presenter and panelist
at the 10th Annual BIO CEO & Investor Conference. Dr. Ezrin will provide an
update on the Company's preparations for the planned Phase III trial for
Neuradiab, a treatment for newly diagnosed glioblastoma multiforme (GBM), the
most common form of brain cancer. The conference is being held at the Waldorf
Astoria Hotel in New York City and Bradmer's corporate presentation is
scheduled on Tuesday, February 12th at 2:45 PM ET in the Bleekman Suite. Dr.
Ezrin will also be a panelist at the Neuro-Oncology Workshop, Neuro-oncology:
"Breaking Down the Barriers to New Neuro-Oncology Drugs" session on Monday,
February 11th from 9:30 to 10:55 AM ET in the East Foyer.
For more information on the BIO CEO & Investor Conference, visit the
conference website at http://ceo.bio.org.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of new and innovative cancer therapies.
Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University
Medical Center as a proprietary therapy for a particularly aggressive form of
brain cancer, glioblastoma multiforme. To date, over US$60 million in grants
and related support has driven research and development of the licensed
treatment, which has been delivered to over 200 patients with promising
results and has completed Phase II clinical trials at Duke University. Bradmer
is currently in the process of organizing a pivotal multi-center clinical
trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status
by both the U.S. Food and Drug Administration and the European Medicines
Bradmer Pharmaceuticals Inc.'s common shares have not been registered
under the Securities Act of 1933, as amended (the "Securities Act") or any
state regulatory agency in the United States. The resale or transfer by a U.S.
investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to
the requirements of Rule 904 of Regulation S of the Securities Act or such
other applicable exemption thereunder, and other applicable state securities
Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risks and
uncertainties, which may include but are not limited to, the receipt of all
regulatory approvals required to conduct the proposed clinical trial of
Neuradiab, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from time
to time in the Company's ongoing quarterly and annual reporting.
For further information:
For further information: Bradmer Pharmaceuticals Inc.: Mr. Brian
Brohman, Chief Business Officer, Phone: (416) 361-6058 (Ext. 804), E-mail:
firstname.lastname@example.org, Internet: www.bradmerpharma.com; Investor
Relations: Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext.
238), Fax: (416) 815-0080, E-mail: email@example.com